Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial.
A novel combination therapy shows early promise and acceptable tolerability in advanced triple-negative breast cancer, requiring larger testing.
A single-arm phase 1b/2 study evaluated pumitamig plus nab-paclitaxel in advanced or metastatic triple-negative breast cancer. Early activity was encouraging and no treatment-related deaths occurred, but randomized confirmation is required.
What the study was
- Study design
- Single-arm phase 1b/2 clinical trial
- Population
- Patients receiving first-line therapy for advanced or metastatic triple-negative breast cancer
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- The Lancet. Oncology
Why it surfaced
The trial reports clinically relevant early efficacy in an aggressive cancer, with single-arm and early-phase limitations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.